Analysis of antibiotic resistance and virulence patterns in Klebsiella pneumoniae isolated from human urinary tract infections in India

In this study, 504 urine samples collected from patients suffering from urinary tract infection (UTIs) were screened for the presence of Klebsiella pneumoniae. The overall occurrence of Klebsiella spp. and K. pneumoniae was found to be 23·2% (117/504) and 16·8% (85/504) respectively. Antibiotic susceptibility testing of 85 K. pneumoniae isolates was carried out by disc diffusion which revealed alarming levels of antibiotic resistance (ABR). Antimicrobial resistance was prominently observed against cefpodoxime (76·47%) followed by ampicillin (70·59%), ceftriaxone (52·94%), cefoxitin (50·59%), amoxyclav (48·24%), ofloxacin (45·88%), cefotaxime (44·71%), cefepime (43·53%) and doxycycline hydrochloride (40%). A small percentage of strains also exhibited resistance to other antimicrobials in the range of 7–35%. Around 77·6% of the isolates were found to be resistant to three or more antibiotic classes and 66·7% of the isolates had multiple antibiotic resistance index values >0·2. Screening of virulence genes in 85 K. pneumoniae isolates revealed that uge gene was the most predominant (11/85, 12·9%), followed by rmpA (9/85, 10·5%), kfu (4/85, 4·7%) and aerobactin genes (2/85, 2·35%). Further, the overall percentage of biofilm producers were found to be 17·65% (15/85). This study warrants hospitals and health care centres to reduce misuse of antibiotics and manage UTI with appropriate treatment after performing antibiotic susceptibility testing.     

A comparative study of induction of pneumonia in mice with planktonic and biofilm cells of Klebsiella pneumoniae

In the present study, the course of acute pneumonia in normal BALB/c mice infected by intranasal inoculation of planktonic and preformed biofilm cells (3 days old) of Klebsiella pneumoniae B5055 was studied and compared. With both cell forms the peak of infection was observed on the third post infection day, as assessed on the basis of lung bacterial load and corresponding pathology. There was an intense neutrophil infiltration in bronchoalveolar lavage fluid. Tissue damage was assessed on the basis of increased amounts of nitrite, malondialdehyde and lactate dehydrogenase in lung homogenates. The phagocytic potential of alveolar macrophages was lower in biofilm cell-induced infection than in that induced by planktonic cells. Biofilm cell induced infection generated significantly greater production of tumor necrosis factor-α and interleukin-1β on the third and fifth days of infection, respectively. Production of interleukin-10 was, however, variable. There was no significant difference in the ability of planktonic and biofilm cell forms of K. pneumoniae to induce acute pneumonia in mice in terms of bacterial counts and histopathological changes. However, biofilm cell-induced infection showed delayed clearance as compared to infection induced with the planktonic form.     

肺炎克雷伯菌生物膜对小鼠腹腔巨噬细胞TLRs受体表达的影响

目的研究肺炎克雷伯菌生物膜对小鼠腹腔巨噬细胞TEas受体表达的影响,探索机体抗生物膜（biofdm,BF）感染免疫的特点。方法将雄性昆明种小鼠40只随机分成2组,一组腹腔植入体外形成肺炎克雷伯菌生物膜的硅胶片,建立留置性医疗装置BF感染模型实验组,另一组植入与实验组同等量的浮游菌作为对照组。实时定量PCR分析2组巨噬细胞TLRsmRNA的表达水平,流式细胞仪检测分析蛋白的表达水平。结果实验生物膜组巨噬细胞TLR2、TLR4mRNA相对表达量是对照浮游菌组的0．23和0．24倍：实验组TLR2、TLR4蛋白表达率分别是（23．27±2．73）％和（15．83±2．04）％,明显低于对照组的（33．42±3．72）％、（21．75±1．25）％（P〈0．05）。结论与浮游菌相比,BF能下调小鼠腹腔巨噬细胞TLR2、TLR4表达,从而影响机体的免疫功能,这可能是BF相对浮游菌更容易逃脱机体免疫防御系统、引起慢性感染的机制之一。     

肺炎克雷伯菌临床分离株的庆大霉素耐药性和细菌铁载体的作用

目的 研究临床分离的肺炎克雷伯菌对氨基糖苷类抗生素庆大霉素的耐药性与其产铁载体的关系。方法 采用K-B纸片法和肉汤稀释法确定70株临床分离的肺炎克雷伯菌对庆大霉素的药物敏感性;CAS琼脂实验检测肺炎克雷伯菌是否产铁载体;紫外可见分光光度法确定细菌产铁载体的量,根据中位数法将70株临床分离菌分为铁载体高产组（35株）和低产组（35株）;应用SPSS统计学软件分析抗生素耐药性与其产铁载体是否相关。结果 药物敏感性试验检测出菌株对庆大霉素的耐药率为50.00%（35/70）;铁载体检测实验确定70株肺炎克雷伯菌均产生铁载体,肺炎克雷伯菌对庆大霉素的耐药性与铁载体产量呈正相关关系（r=0.3154,P<0.05）,对庆大霉素耐药菌株铁载体产量明显高于敏感菌株（t=3.1650,P<0.05）,且铁载体高产组耐药率及lgMIC值明显高于低产组（χ2=9.6570,t=3.1360,P<0.05）。结论 70株临床分离的肺炎克雷伯菌均产生铁载体,铁载体可能参与肺炎克雷伯菌对庆大霉素的耐药,干扰庆大霉素的抑菌或杀菌过程。     

肺炎克雷伯菌生物膜对小鼠巨噬细胞免疫功能的影响

目的研究肺炎克雷伯菌生物膜(BF)对小鼠腹腔巨噬细胞TLRs mRNA和细胞因子表达的影响,探索机体抗BF感染免疫的特点。方法将雄性昆明种小鼠40只随机分成2组,一组腹腔植入体外形成肺炎克雷伯菌BF的硅胶片,建立留置性医疗装置BF感染模型实验组,另一组植入与实验组同等量的浮游菌作为对照组。实时定量PCR分析2组巨噬细胞TLRs mRNA的表达水平,双抗体夹心ELISA法测定细胞因子的含量。结果实验BF组巨噬细胞TLR2、TLR4 mRNA表达量是对照浮游菌组的0.23和0.24倍;而TLR5、TLR9两组表达差异无显著性。实验BF组刺激前后IL-1、IL-2的差值明显低于对照浮游菌组,而IL-4则相反(P0.01)。结论与浮游菌相比,BF能下调小鼠腹腔巨噬细胞TLR2、TLR4的表达,机体的免疫应答朝着Th2型免疫反应发展,这可能是BF相对浮游菌更容易逃脱机体免疫防御系统、引起慢性感染的机制之一。     

仙居县儿童下呼吸道感染肺炎克雷伯菌耐药性分析

目的分析仙居人民医院住院下呼吸道感染患儿临床分离肺炎克雷伯菌的耐药特征,为临床合理用药提供依据。方法选择2012年7月至2013年7月该院下呼吸道感染肺炎克雷伯菌阳性患儿81例。对患儿的临床一般资料进行分析,对临床分离菌株进行细菌鉴定,用18种抗生素进行药敏试验,采用WHONET5．4分析软件进行统计。结果2012年7月至2013年7月共分离出81株肺炎克雷伯菌,ESBLs阳性42株,检出率为51．85％。所有菌株对亚胺培南、厄他培南、左旋氧氟沙星、丁胺卡那100％敏感。对氨苄西林耐药率为100％。ESBLs阴性菌株对氨曲南、头孢曲松、头孢他啶、头孢唑啉、头孢吡肟100％敏感,而ESBLs阳性菌株则100％耐药。ESBLs阴性菌株对其他抗生素的耐药率为氨苄西彬舒巴坦（12．82％）、环丙沙星（2．56％）、头孢替坦（O％）、呋喃妥因（20．51％）、庆大霉素（5．13％）、复方新诺明（17．85％）、妥布霉素（2．56％）、哌拉西林／他唑巴坦（2．56％）;ESBLs阳性菌株对其他抗生素的耐药率为氨苄西林／舒巴坦（73．80％）、环丙沙星（2．38％）、头孢替坦（16．67％）、呋喃妥因（61．90％）、庆大霉素（28．57％）、复方新诺明（54．76％）、妥布霉素（7．14％）、哌拉西林／他唑巴坦（7．14％）。结论本地区患儿中肺炎克雷伯菌耐药性较高,临床应重视病原菌的检测。     

临床分离肺炎克雷伯菌Ⅰ整合子分布及其与qnr基因关系研究

目的 了解临床分离肺炎克雷伯菌中qnr基因和Ⅰ类整合子基因的分布及其耐药特征.方法 采用PCR法对45株耐环丙沙星肺炎克雷伯菌进行qnrA、qnrB、qnrS基因筛查并测序,用PCR法检测qnr阳性菌株Ⅰ类整合子基因,并采用SPSS 13.0和Whonet 5.4软件分析药敏结果及比较.结果 45株肺炎克雷伯菌中,24株(51.1％)细菌检出qnrS基因,未检出qnrA和qnrB基因.20株qnr阳性菌株同时携带Ⅰ类整合子基因.qnr阳性菌株Ⅰ类整合子基因携带率显著高于阴性菌株,qnr阳性菌株对阿米卡星、妥布霉素、亚胺培南、哌拉西林/他唑巴坦及头孢哌酮舒巴坦的敏感性较高.结论 肺炎克雷伯菌对氟喹诺酮类抗菌药物耐药主要由qnrS引起,qnr阳性株同时携带Ⅰ类整合子,导致呈现多重耐药性,加强临床耐药监测对控制多重耐药传播有着重要的意义.     

耐碳青霉烯类肺炎克雷伯菌血流感染危险因素及预后分析

目的 探讨碳青霉烯类耐药肺炎克雷伯菌血流感染（CSKP）的危险因素以及影响患者28 d预后的相关因素。方法 回顾性分析我院2016年1月至2017年12月期间住院的肺炎克雷伯菌血流感染患者的临床病史资料,按患者血培养标本采集后28 d内预后情况分为存活组与死亡组,应用单因素分析及多因素Logistic回归分析探讨碳青霉烯耐药肺炎克雷伯菌血流感染的危险因素,应用Cox回归分析研究影响肺炎克雷伯菌血流感染28 d预后的相关因素。结果 耐碳青霉烯类肺炎克雷伯菌血流感染的危险因素包括高APACHEⅡ评分、高Pitt菌血症评分、感染时入住ICU、感染前30 d内手术、有创操作、深静脉置管、有创机械通气、器官移植、使用免疫抑制剂、感染前3个月内入住ICU和感染前使用抗菌药物。Logistic回归分析显示高APACHEⅡ评分（OR=1.066,95% CI：1.027~1.107,P=0.001）、手术（OR=3.777,95% CI：1.816~7.855,P<0.001）、有创操作（OR=2.864,95% CI：1.303~6.295,P=0.009）、器官移植（OR=3.892,95% CI：1.553~9.752,P=0.004）、感染前使用抗菌药物（OR=5.626,95% CI：2.740~11.553,P<0.001）是发生碳青霉烯类耐药的肺炎克雷伯菌血流感染的独立危险因素。影响肺炎克雷伯菌血流感染28 d预后的相关因素有高APACHEⅡ评分、高Pitt菌血症评分、感染时入住ICU、感染前30 d内手术、有创操作、深静脉置管、有创机械通气、器官移植、感染前3个月内ICU入住史、使用抗菌药物、粒细胞缺乏、血液透析和菌株对碳青霉烯类耐药。Cox回归分析发现高APACHEⅡ评分（HR=1.061,95% CI：1.039~1.084,P<0.001）、有创操作（HR=2.505,95% CI：1.239~5.063,P=0.011）、入住ICU（HR=1.589,95% CI：1.042~2.424,P=0.031）是影响患者预后的独立危险因素。耐碳青霉烯类肺炎克雷伯菌（CRKP）血流感染患者的28 d病死率明显高于碳青霉烯类敏感肺炎克雷伯菌感染患者（χ2=41.612,P<0.001）。结论 高APACHEⅡ评分、手术、有创操作、器官移植、感染前使用抗菌药物可导致耐碳青霉烯类肺炎克雷伯菌血流感染的发生风险增加。CRKP血流感染患者死亡率显著高于CSKP感染者,但CRKP感染并非患者短期死亡的独立危险因素。而高APACHEⅡ评分、有创操作、入住ICU则可显著增加患者短期病死率。     

多重耐药肺炎克雷伯菌肺部感染的抗感染治疗新策略

目的 尝试使用新的抗感染治疗策略治疗多重耐药肺炎克雷伯菌肺部感染。方法 选择10例转入ICU的院内获得性肺部感染患者,入选患者使用抗生素治疗效果不佳,多次痰培养结果提示多重耐药的肺炎克雷伯菌生长。患者先予以头孢美唑抗感染治疗,在48~72 h后痰培养结果均提示对亚胺培南等敏感的铜绿假单胞菌生长,然后根据患者肺部感染是否好转选择继续使用头孢美唑或调整为对铜绿假单胞菌有效的抗生素。结果 10例患者治疗7 d后C反应蛋白（CRP）、降钙素原（PCT）、临床肺部感染评分（CPIS）均显著下降（P＜0.05）,所有患者均顺利脱机拔管转出ICU。结论 根据肺部微生态特点,利用菌群之间存在的拮抗作用,可以使用抗生素来调节微生态失衡。对于合适的患者,这种新的抗感染策略可以有效治疗多重耐药肺炎克雷伯菌肺部感染,可作为临床抗感染策略之一。     

临床分离肺炎克雷伯菌耐药性监测

目的了解临床分离肺炎克雷伯菌的耐药性,为临床合理应用抗菌药物提供实验室依据。方法采用微量稀释法对392例临床分离肺炎克雷伯菌进行药物敏感性测定;超广谱β-内酰胺酶(Extendedspectrumbeta-lactamases,ESBLs)检测用微量稀释法初筛,纸片法做确证试验。结果肺炎克雷伯菌对18种抗菌药物的药敏结果中,耐药率大于30%的抗菌药物多达11种;其中氨苄西林-舒巴坦、氨苄西林、头孢噻吩、哌拉西林、复方新诺明和头孢唑啉的耐药率高达20%以上。耐药率低于10%的抗菌药物仅有4种,分别为头孢曲松(7.7%)、头孢噻肟(7.4%)、氨曲南(6.9%)和亚胺培南(3.1%)。其它抗菌药物的耐药率都高于10%。产ESBLs菌株的发生率为32.9%～45.8%,平均为39.8%;产ESBLs菌株对多种抗菌药物的耐药率显著高于非产ESBLs菌株(P<0.05)。结论临床分离肺炎克雷伯菌对多种抗菌药物的耐药率较高,尤其是产ESBLs菌株的高耐药率及多重耐药性更为明显。临床应加强对肺炎克雷伯菌耐药性的监测并预防耐药菌株的传播流行。     

肺炎克雷伯菌致肺癌患者术后肺部感染的病因与耐药性分析

目的探讨肺癌术后并发肺炎克雷伯菌肺部感染的病因和耐药情况,为术后肺炎克雷伯菌感染的预防和治疗提供病原学依据。方法收集2011年1月1日至2014年6月30日本院肺癌术后合并肺部感染患者下呼吸道标本,常规分离培养肺炎克雷伯菌,K-B纸片法进行药敏试验,利用WHONET 5.6软件分析处理试验数据。结果从肺癌术后患者下呼吸道分离的肺炎克雷伯菌产ESBLs高,达68.1%;对头孢替坦、阿米卡星、亚胺培南和美罗培南都较敏感,耐药率分别为6.0%、21.4%、18.1%和20.9%,其余抗菌药物的耐药率均30.0%。结论肺癌术后并发肺炎克雷伯菌肺部感染耐药率高,对碳青霉烯类抗菌药物仍保持高度敏感性,临床应加强耐药性监测,并根据药敏试验结果合理选用抗菌药物。     

Mini-review: Staphylococcus epidermidis as the most frequent cause of nosocomial infections: old and new fighting strategies

Staphylococcus epidermidis is nowadays regarded as the most frequent cause of nosocomial infections and indwelling medical device-associated infections. One of the features that contributes to the success of this microorganism and which is elemental to the onset of pathogenesis is its ability to form biofilms. Cells in this mode of growth are inherently more resistant to antimicrobials. Seeking to treat staphylococcal-related infections and to prevent their side effects, such as the significant morbidity and health care costs, many efforts are being made to develop of new and effective antistaphylococcal drugs. Indeed, due to its frequency and extreme resistance to treatment, staphylococcal-associated infections represent a serious burden for the public health system. This review will provide an overview of some conventional and emerging anti-biofilm approaches in the management of medical device-associated infections related to this important nosocomial pathogen.     

Effect of chlorhexidine and benzalkonium chloride on bacterial biofilm formation

AIM: To study the effect of antiseptics on bacterial biofilm formation. METHODS AND RESULTS: Biofilm formation and planktonic growth were tested in microtiter plates in the presence of antiseptics. For Escherichia coli G1473 in the presence of chlorhexidine or benzalkonium chloride, for Klebsiella pneumoniae CF504 in the presence of chlorhexidine and for Pseudomonas aeruginosa PAO1 in the presence of benzalkonium chloride, biofilm development and planktonic growth were affected at the same concentrations of antiseptics. For PAO1 in the presence of chlorhexidine and CF504 in the presence of benzalkonium chloride, planktonic growth was significantly inhibited by a fourfold lower antiseptic concentration than biofilm development. For Staphylococcus epidermidis CIP53124 in the presence of antiseptics at the minimal inhibitory concentration (MIC), a total inhibition of biofilm formation was observed. For Staph. epidermidis exposed to chlorhexidine at 1/2, 1/4 and 1/8 MIC, or to benzalkonium chloride at 1/8, 1/16 or 1/32 MIC, biofilm formation was increased from 11.4% to 22.5% without any significant effect onto planktonic growth. CONCLUSIONS: Chlorhexidine and benzalkonium chloride inhibited biofilm formation of different bacterial species but were able to induce biofilm development for the Staph. epidermidis CIP53124 strain at sub-MICs. SIGNIFICANCE AND IMPACT OF THE STUDY: Sublethal exposure to cationic antiseptics may contribute to the persistence of staphylococci through biofilm induction.     

2014—2016年大连地区血流感染肺炎克雷伯菌的耐药性特征分析

目的 分析肺炎克雷伯菌所致血流感染患者的科室分布及其病原菌耐药性特征,为指导临床合理应用抗菌药物,有效控制感染提供依据。方法 选择2014—2016年大连医科大学附属第一医院送检血液标本中分离得到的289株肺炎克雷伯菌,对其进行细菌鉴定、药敏试验及ESBL确认试验,分析肺炎克雷伯菌所致血流感染的科室分布特征及其病原菌耐药性变迁。结果 患者血液中肺炎克雷伯菌检出率以急诊科（24.91%）和ICU为最高（23.88%）。3年中肺炎克雷伯菌对碳青霉烯类抗生素和阿米卡星耐药率较低,均在20.00%左右。产ESBL肺炎克雷伯菌共135株,占46.71%,对常用抗生素的耐药率均显著高于非产ESBL菌株（P<0.01）。碳青霉烯类抗生素耐药菌株对常用抗生素耐药率均高于敏感菌株（P<0.01）,对四环素、复方新诺明和阿米卡星耐药率相对较低,分别为66.10%、66.10%、71.19%。结论 我院2014—2016年患者血液中肺炎克雷伯菌检出率以急诊科和ICU为最高。该菌对碳青霉烯类抗生素及阿米卡星的耐药率较低,碳青霉烯类抗生素耐药菌株对四环素、复方新诺明和阿米卡星尚有一定敏感性。     

2016—2018年某医院肺炎克雷伯菌的临床分布及耐药性分析

目的分析某院肺炎克雷伯菌(Klebsiella pneumoniae, KPN)的临床分布,产超广谱β-内酰胺酶(extended-spectrum β-lactamase, ESBLs)的情况以及综合耐药特点,为临床经验性选用抗生素提供参考。方法回顾性分析某院2016-2018年临床分离培养的KPN耐药数据及临床资料,菌株均采用全自动分析仪进行菌种鉴定和药敏分析。结果 3年间共检出非重复KPN 2 211株,样本分布结果显示,KPN最多的是痰液1 268株,占57.35%;脑脊液最少12株,仅占0.54%。临床科室分布来看,ICU病房分离KPN最多274株,占12.39%;乳甲外科最少5株,仅占0.23%。2 211株KPN共检出ESBLs阳性708株,检出率为32.02%。KPN对头孢唑林、头孢呋辛、头孢曲松和复方新诺明的耐药率均已超过40%,对亚胺培南、阿米卡星和美罗培南耐药率仅为5.20%。与胆汁、血液和痰液样本中KPN的耐药性相比,尿液分离株的耐药性普遍较高(P<0.05)。结论 ESBLs检出率较高,耐药情况较为严峻,并且不同样本来源菌株的耐药性有较大差异,以尿液分离株的耐药性更为严重。医院需加强对重点科室,不同样本中KPN的耐药性监测,合理使用抗生素。     

Two different types of fosfomycin resistance in clinical isolates of Klebsiella pneumoniae

Abstract The fosfomycin susceptibility of 100 clinical isolates of Klebsiella pneumoniae and the resistance mechanisms utilized by resistant strains were examined. Washed cells prepared from the strains demonstrating MICs of more than 8 μg ml⁻¹ of fosfomycin inactivated the drug. A crude extract from strain Tf129B, highly resistant to fosfomycin, was used to study the enzymatic properties of the drug-inactivating enzyme. The optimum pH for inactivation was 7.8 and the optimum temperature of the reaction was 37°C. Glutathione was shown to be effective as a cofactor in the inactivation. It was suggested that the inactivating enzyme of Klebsiella pneumoniae was fosfomycin: glutathione-S-transferase, a constitutive enzyme located in the periplasmic space. A good correlation was found between the specific activities of this enzyme and the MIC levels; however, certain strains showed a low level of fosfomycin: glutathione-S-transferase activity which could not account for the increased MIC. Strains Tf129B and Tf408E, both demonstrating MICs of more than 1024 μg ml⁻¹ of fosfomycin carried a transferable resistance plasmid. In strain Tf129B, the mechanism of fosfomycin resistance was due to a high level of enzymic activity. In strain Tf408E, it was determined to be mainly due to the reduced permeability of the cell membrane.     

血流感染大肠埃希菌和肺炎克雷伯菌的ESBLs基因分型

目的 了解深圳市人民医院致血流感染大肠埃希菌和肺炎克雷伯菌超广谱β-内酰胺酶(ESBLs)的检出率及基因型特点.方法 收集来自临床血液培养标本中的大肠埃希菌和肺炎克雷伯菌115株,采用ESBLs表型确证试验检测菌株的ESBLs,应用PCR扩增产ESBLs菌株TEM、SHV和CTX-M基因,并对阳性扩增产物进行DNA测序分型.结果 115株菌中共检出ESBLs阳性38株,检出率为33.0％;其中大肠埃希菌阳性25株,肺炎克雷伯菌阳性13株.25株产酶肠埃希菌中18株检出CTX-M-14基因,3株检出CTX-M-9基因.13株产酶肺炎克雷伯菌均检出SHV型基因,其中SHV-12阳性10株,SHV-2阳性2株,SHV-59阳性1株;该13株产酶菌中10株同时被检出含CTX-M-14或CTX-M-13基因.结论 该院致血流感染大肠埃希菌产ES-BLs以CTX-M-14为最主要基因型,肺炎克雷伯产ESBLs最常见为SHV-12和CTX-M-14型.     

阿萨希毛孢子菌的溶血活性及生物膜形成能力与其基因型关系研究

目的 分析临床分离自尿路感染患者的阿萨希毛孢子菌的体外溶血活性及生物膜形成能力与其基因型的关系,为临床诊治提供依据.方法 玻璃珠法提取总DNA,并采用PCR技术利用IGS1区特异性引物确定其基因型别;同时,平板法和XTT还原比色法分别检测阿萨希毛孢子菌的溶血活性及生物膜形成能力,并分析其与基因型的关系.结果 10株分离自尿路感染的阿萨希毛孢子菌基因型分别属于Ⅰ、Ⅲ、Ⅳ,其中以Ⅳ型为主;所分离菌株均具有不同程度的溶血活性;除1例分离株外,其余各分离株均具有在聚苯乙烯表面形成生物膜的能力;基因型Ⅲ型菌株具有较强的溶血活性和生物膜形成能力.结论 分离自尿路感染患者的10株阿萨希毛孢子菌以Ⅳ型为主,而其中Ⅲ型菌株表现出较强的溶血活性和生物膜形成能力.